BioSpace News Archive

Business

BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2022.

November 9, 2022
·
10 min read
Freeline to Present at the Stifel 2022 Healthcare Conference

Freeline Therapeutics Holdings plc announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.

November 9, 2022
·
1 min read
Business

Odyssey Therapeutics Expands Management Team with Key Appointments in Research Development and Strategy

Odyssey Therapeutics, Inc. today announced the appointment of Jeff Hermes, Ph.D., as Executive Vice President of Enabling Sciences and promotion of Natalie Dales, Ph.D., to the newly created position of Chief of Research Operations and Portfolio Strategy.

November 9, 2022
·
3 min read
Business

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2022.

November 9, 2022
·
9 min read
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 09, 2022

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 104,000 shares of its common stock to four employees outside Fusion’s 2020 Stock Option and Incentive Plan.

November 9, 2022
·
2 min read
Business

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Vera Therapeutics, Inc. today reported its business highlights and financial results for the quarter ended September 30, 2022.

November 9, 2022
·
10 min read
Business

BeiGene Reports Third Quarter 2022 Financial Results

BeiGene, Ltd. today reported financial results for the third quarter of 2022, recent business highlights, and anticipated upcoming milestones.

November 9, 2022
·
22 min read
Business

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress, business updates and reported financial results for the third quarter ended September 30, 2022.

November 9, 2022
·
16 min read
Genetown

Alnylam to Webcast Presentations at Upcoming November 2022 Investor Conferences

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present company overviews at the following conferences.

November 9, 2022
·
2 min read
Genetown

Astria Therapeutics to Present at Upcoming 2022 Jefferies London Healthcare Conference

Astria Therapeutics, Inc. announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming Jefferies London Healthcare Conference on Wednesday, November 16th at 7:25am GMT.

November 9, 2022
·
1 min read